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The human hMYH and NEIL1 genes encode DNA glycosylases
involved in repair of oxidative base damage and mutations in
these genes are associated with certain cancers. Primary scleros-
ing cholangitis (PSC), a chronic cholestatic liver disease charac-
terized by inﬂammatory destruction of the biliary tree, is often
complicated by the development of cholangiocarcinoma (CCA).
Here, we aimed to investigate the inﬂuence of genetic variations in
the hMYH and NEIL1 genes on risk of CCA in PSC patients. The
hMYH and NEIL1 gene loci in addition to the DNA repair genes
hOGG1, NTHL1 and NUDT1 were analyzed in 66 PSC patients
(37 with CCA and 29 without cancer) by complete genomic se-
quencing of exons and adjacent intronic regions. Several single-
nucleotide polymorphisms and mutations were identiﬁed and
severe impairment of protein function was observed for three
non-synonymous variants. The NEIL1 G83D mutant was
dysfunctional for the major oxidation products 7,8-dihydro-8-
oxoguanine (8oxoG), thymine glycol and dihydrothymine in du-
plex DNA, and the ability to perform d-elimination at abasic sites
was signiﬁcantly reduced. The hMYH R260Q mutant had severe
defect in adenine DNA glycosylase activity, whereas hMYH
H434D could excise adenines from A:8oxoG pairs but not from
A:G mispairs. We found no overall associations between the 18
identiﬁed variants and susceptibility to CCA in PSC patients;
however, the impaired variants may be of signiﬁcance for carci-
nogenesis in general. Our ﬁndings demonstrate the importance of
complete resequencing of selected candidate genes in order to
identify rare genetic variants and their possible contribution to
individual susceptibility to cancer development.
Introduction
Oxidative DNA damage induced by reactive oxygen species is a major
sourceofmutationloadinlivingorganismsandisbelievedtoplayacaus-
ative role in aging and degenerative diseases such as cancer (1,2). Re-
active oxygen speciesare formed as by-products of the electron transport
machinery, during conditions of chronic inﬂammation and by exogenous
stimuli such as ionizing radiation and various chemicaloxidants (3). 7,8-
dihydro-8-oxoguanine (8oxoG) is one of the most stable products of
oxidative DNA damage and has deleterious effects because it can mis-
pair with adenine during DNA replication (4,5). Many tumors have been
shown to have G:C to T:A transversion mutations associated with 8oxoG
and also to have increased levels of 8oxoG in the DNA (6–8).
To counteract the potential harmful effects of oxidative DNA dam-
age, cells primarily use the base excision repair (BER) pathway. BER
is initiated by lesion-speciﬁc DNA glycosylases that identify and
excise the damaged base, leaving an abasic (apurinic/apyrimidinic)
site in the DNA that is further processed by the other enzymes of the
BER pathway (reviewed in ref. 9). Mammalian cells are equipped
with several different DNA glycosylases and 8oxoG DNA glycosylase
(hOGG1) is the major enzyme for removal of 8oxoG from an 8ox-
oG:C pair but not when 8oxoG is already mispaired with adenine. In
this case, A is removed by adenine DNA glycosylase (hMutY/hMYH)
(reviewed in ref. 10). Finally, the NUDT1 (MutT in bacteria) enzyme
hydrolyzes 8oxoG triphosphate to 8oxoG monophosphate, thus avoid-
ing the incorporation of oxidized nucleotides into genomic DNA. The
DNA glycosylases endonuclease III (NTHL1) and endonuclease VIII-
like 1 (NEIL1) are the principal enzymes for removal of oxidized
pyrimidines such as thymine glycol (Tg), 5-hydroxy cytosine
(5ohC) and 5-hydroxy uracil (5ohU) (reviewed in ref. 11).
Recent studies suggest that polymorphisms in DNA glycosylase
genesare associatedwithseveralcancers. For example, polymorphisms
in NEIL1 have been linked to gastric cancer (12), whereas those in
hOGG1 have been related to higher risk for prostate (13) and lung
cancer (reviewed inref.14).For the hMYH gene,inactivating mutations
and polymorphisms are associated with development of colorectal pol-
yposis (MutYassociated-polyposis) (7,15). Also, approaches based on
functional analyses have shown that reduced 8oxoG DNA glycosylase
activity is a risk factor in lung, head and neck cancer (16,17).
Primary sclerosing cholangitis (PSC) is a chronic inﬂammatory
disease of the bile ducts leading to bile duct strictures and eventually
livercirrhosisandlivertransplantation(18).Importantly,PSCisacon-
siderable risk factor for the development of cholangiocarcinoma
(CCA) that results from a malignant transformation of bile duct epi-
thelial cells. The prevalence of CCA in PSC ranges from 6–13% in
most reports (19–21). The duration and severity of PSC does not seem
to correlate with development of CCA, suggesting that individual
susceptibility factors are important (22,23). As recently demonstrated
(24), genetic variants may inﬂuence risk of CCA in PSC. Further, an
emerging concept in association studies is that rare sequence variants
with strong phenotypic effects might contribute substantially to the
aggregated risk of complex traits, including cancer. The exact mech-
anism for CCA development in PSC is unknown. In experimental
models, bile has been shown to induce oxidative stress and to increase
oxidative DNA damage in cholangiocytes (25). Consequently, indi-
vidual differences in processing of DNA damage could be of impor-
tance for transformation of the inﬂammatory changes of the biliary
tree into cancer. In this study, we have evaluated the role of germ line
variation in genes important for repair of oxidative DNA damage and
their potential role for development of CCA in PSC patients.
Materials and methods
Patients and controls
The studyincluded 66 ScandinavianPSC patientsrecruited on admissionto the
Medical Department, Rikshospitalet University Hospital, Oslo, Norway,
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phoretic mobility shift assay; 5ohC, 5-hydroxy cytosine; 5ohU, 5-hydroxy
uracil; 8oxoG, 7,8-dihydro-8-oxoguanine; PSC, primary sclerosing cholangi-
tis; SNP, single-nucleotide polymorphism; ssDNA, single-stranded DNA; Tg,
thymine glycol; WT, wild-type.
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versity Hospital, Huddinge, Stockholm, Sweden (n 5 18). PSC was diagnosed
according to accepted criteria, including characteristic cholangiographic ﬁnd-
ings (18). Inﬂammatory bowel disease was diagnosed by colonoscopy with
biopsies and classiﬁed according to standard criteria. The cohort comprised 37
(28 males) PSC patients with CCA (one patient with a carcinoma of the
gallbladder was included in this group) and 29 (20 males) without cancer of
the biliary tract. CCAwas conﬁrmed by histology. Concomitant inﬂammatory
bowel disease had been diagnosed in 78% of the patients with CCA and in 86%
of those without. An ethnically matched group of healthy controls (n 5 30)
was randomly selected from the Norwegian Bone Marrow Donor Registry. All
participants gave their written informed consent. The study was approved by
The Regional Committee for Research Ethics in Southern Norway and The
Ethics Committee of Karolinska Institutet.
DNA sequencing
Genomic DNA was extracted from peripheral blood leukocytes from PSC
patients and controls and whole genome ampliﬁcation was performed using
the GenomiPhi kit (GE Healthcare Systems, Chalfont St Giles, UK), yielding
high molecular ampliﬁed DNA thoroughly validated for genotyping (26).
The exons including ﬂanking intronic regions of the genes hMYH, hOGG1,
NEIL1, NUDT1 and NTHL1 were ampliﬁed using primers listed in supplemen-
tary Table 1 (available at Carcinogenesis Online). Detailed polymerase chain
reaction conditions are freely available from the authors upon request. Sub-
sequent sequencing (primers available upon request) was performed with Big-
Dye Terminator v3.1 chemistry (Applied Biosystems, Foster City, CA) and
an ABI3730 capillary sequencer (Applied Biosystems) according to manufac-
turer’s protocols. Subsequent mutation detection was performed using Seq-
Scape v2.5 (Applied Biosystems).
Construction and puriﬁcation of hMYH, hOGG1 and NEIL1mutants
Primers used for site-speciﬁc mutagenesis are listed in supplementary Table 2
(available at Carcinogenesis Online). pGEV1-hMYH (27) was used to generate
the three hMYH mutants (R260Q, H434D and S501F) with QuickChange poly-
merase chain reaction. The hOGG1 gene was subcloned from pUC18-hOGG1
(28) into the EcoRI and BglII sites of pETDuet-1 (Novagen, Madison, WI) and
this construct was used as the template to generate pETDuet-1-hOGG1-S31P.
NEIL1cDNA subcloned into the NdeI and XhoI sites of pET22b was used as
template to generate the two mutated constructs pET22b-NEIL1-G83D and
pET22b-NEIL1-E181K. All constructs were veriﬁed by DNA sequencing of
the entire open readingframes. Proteinswere expressed in Escherichia coliand
puriﬁed as described in supplementary Data (available at Carcinogenesis On-
line). Puriﬁed proteins were analyzed by sodium dodecyl sulfate–polyacryl-
amide gel and detected by Coomassie Blue staining (supplementary Figure 1 is
available at Carcinogenesis Online).
Assays for DNA glycosylase activity
Substrates for enzyme cleavage analysis were: 5#-ctcggtacccggggatctggccat-
g[A]ccgtgcaggcatgc (8oxoG or G opposite the marked A gave the A:8oxoG
and A:G substrates, respectively); 5#-ggcggcatgaccc[8oxoG]gaggcccatc (C
opposite 8oxoG gave the 8oxoG:C substrate); 5#-ctcgtcagcatca[Tg]catcata-
cagtcagtg (to yield the stereoisomer 5R Tg:A substrate) and 5#-gcatgcctg-
cacgg[x]catggccagatccccgggtaccgag [x is dihydrothymine (DHT), 5ohC,
5ohU or U with A, G, G or G, respectively, opposite the damage in the
complementary strand gave the DHT:A, 5ohC:G, 5ohU:G or U:G substrates).
All oligonucleotides were 5# end labeled with T4 polynucleotide kinase (New
EnglandBiolabs,Ipswich,MA)and [c-32P]adenosinetriphosphate(Amersham
Biosciences, Pittsburgh, PA). In order to generate double-stranded substrates,
the labeled oligonucleotides were annealed to their respective complementary
strands by heating the solution to 90C for 2 min followed by slow cooling to
room temperature. The U:G substratewas treated with uracil DNA glycosylase
(New England Biolabs) to make the apurinic/apyrimidinic substrate.
Enzyme reactions were carried out in 70 mM 3-(N-morpholino)propanesul-
fonic acid, pH 7.5, 1 mM dithiothreitol, 1 mM ethylenediaminetetraacetic acid
and 5% glycerol for 30 min at 37C. Reaction mixtures contained 10 fmol
substrate and enzymes as indicated in the ﬁgures in a total volume of 10 ll. To
obtain strand cleavage after hMYH and hOGG1 base removal, NaOH (100
mM) was added to the reactions and incubation continued at 70C for 15 min
before neutralization with HCl (100 mM). All reactions were stopped by add-
ing formamide DNA loading buffer. The reaction products were analyzed by
20% denaturing polyacrylamide gel electrophoresis and bands visualized by
Phosphorimaging. Quantiﬁcations were done with the ImageQuant Software.
FaPy DNA glycosylase assays were done in the same reaction buffer as
above and [N-3H]methyl-N#-nitrosourea (18 Ci/mmol) was used to prepare
poly (dG dC) DNA containing faPy residues (5000 d.p.m./lg DNA) as de-
scribed (29). Brieﬂy, DNA glycosylase activity was measured in a total volume
of 50 ll containing 0.4 lg[ 3H-]faPy-poly(dG-dC) with different amounts of
enzyme as indicated. After incubation at 37C for 30 min, DNA was precip-
itated with ethanol. The radioactivity of the supernatant was determined by
scintillation counting.
Electrophoretic mobility shift assays
DNA binding of hMYH variants was determined by electrophoretic mobility
shift assays (EMSAs) using 32P-5#-end labeled duplex DNA substrates con-
taining an A:8oxoG or an A:G basepair. DNA (10 fmol) and enzymes as
indicated in the ﬁgure were incubated on ice for 30 min in 20 mM Tris–
HCl (pH7.5), 80 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1 mM
dithiothreitol and 3% glycerol in a total volume of 10 ll. Two-hundred
femtomole competitor DNA (same duplex without damage) was included
in all reactions. Reactions were stopped by adding 2 ll6   DNA loading
buffer (Fermentas, Ontario, Canada). Samples were analyzed on 10% native
polyacrylamide gel electrophoresis in 1  Taurin at 4C and visualized by
Phosphorimaging. EMSAs for hOGG1 and NEIL1 enzymes were performed
in the same buffer as the DNA glycosylase assays with substrates as indi-
cated. hOGG1 samples were analyzed as for hMYH, whereas the NEIL1
samples were run in 0.5  Tris/Borate/EDTA.
Intracellular localization of NEIL1 variants in HeLa cells
HeLaS3cells werecultivated in Dulbecco’s ModiﬁedEagle’s Mediumwith 4.5
g/l glucose, 10% fetal calf serum, 0.3 mg/ml glutamine, 100 U/ml penicillin
and 0.1 mg/ml streptomycin at 37C in a 5% CO2 air atmosphere. Transfec-
tions of HeLa cells were done using FuGENE 6 Transfection Reagent (Roche
Applied Science, Mannheim, Germany) according to the manufacturer’s rec-
ommendations. Plasmids for transfections were pEGFP-NEIL1 (30), pEGFP-
NEIL1-G83D, pEGFP-NEIL1-E181K and pEGFP-N1 (Clontech, Montain
View, CA) as control. The site-speciﬁc mutants were generated by Quick-
Change polymerase chain reaction with the same primers as for the expression
constructs.
One or two days after transfection, the cells were stained with 5 lg/ml
Hoechst 33342 (H-3570, Molecular Probes, Carlsbad, CA) at 37C for 20 min
and imaged directly with a Zeiss Axiovert 200M ﬂuorescence microscope
(Carl Zeiss, Jena, Germany).
Results
DNA from patients with PSC (n 5 29), PSC with CCA (n 5 37) and
healthy controls (n 5 30) were screened for sequence variations in
the hMYH, hOGG1, NEIL1, NUDT1 and NTHL1genes. In total, 18
sequence variants were identiﬁed in the coding regions of the ﬁve
DNA repair genes examined (Table I). Association analysis with
Bonferoni correction (18 tests) revealed no signiﬁcant differences in
genotype frequencies between PSC patients with and without CCA
(Table I). Of the 18 variants, six were validated single-nucleotide
polymorphisms (SNPs), whereas 12 were novel mutations.
In a functional perspective, two splice site mutations were found in
two healthy controls in the NEIL1 and NUDT1 gene, respectively.
Three of 12 novel mutations were synonymous, whereas nine were
non-synonymous. All these 12 mutations were monoallelic and were
found in the hMYH (4), hOGG1 (5) and NEIL1 (3) genes. For NUDT1,
two frequent SNPs (V83M and D119) were found but no new muta-
tions and, interestingly, no sequence variation at all was identiﬁed in
the NTHL1 gene. All novel non-synonymous mutations (except one
non-synonymous but conservative mutation) identiﬁed in the PSC or
PSC-CCA patients were subjected to functional analysis.
Analysis of hMYH
Of the four non-synonymous hMYH mutations identiﬁed, one was in
the healthy control group (E155Q) and three in the PSC group
(R260Q, H434D and S501F) (Table I, Figure 1A). The S501F muta-
tion was also found in one PSC patient with CCA. From the 3D
structure of MutY from Bacillus stearothermophilus (31), it can be
inferred that amino acid Arg260 in hMYH is located on the surface of
hMYH, on the opposite side of the DNA-binding groove (Figure 1A).
Further, His434 resides within a loop involved in 8oxoG recognition
(Figure 1A) and interacts with the phosphate backbone of the DNA
strand containing 8oxoG. Finally, Ser501 is in a region predicted to be
disordered that is also outside of the structural model of B.stearother-
mophilus MutY.
The three mutations found in the PSC patients were introduced into
hMYH expression plasmids and the mutant proteins were expressed in
M.Forsbring et al.
1148a mutY deﬁcient E.coli strain to avoid contamination of endogenous
MutY. Despite high expression levels, most hMYH was insoluble
(data not shown) and we were able to obtain only partially puriﬁed
hMYH proteins after nickel–agarose puriﬁcation (supplementary
Figure 1 is available at Carcinogenesis Online). Using oligonucleo-
tide substrates with the A:8oxoG at a deﬁned position, hMYH DNA
glycosylase activity can be monitored by running denaturating poly-
acrylamide gels, where the cleaved product (C) after NaOH treatment
will migrate faster than the intact substrate (I; Figure 2A). DNA
glycosylase activity assays revealed that the mutant enzymes hMYH
H434D and hMYH S501F removed adenines from duplex oligonu-
cleotides containing A:8oxoG base pairs at rates comparable with
wild-type (WT) hMYH (Figure 2A). Contrary, for a substrate con-
taining an A:G mispair, hMYH H434D activity was severely re-
duced (4% cleavage as compared with 36% for WT hMYH with
18 ng enzyme), whereas the S501F mutant showed the same A:G
DNA glycosylase activity as intact hMYH (Figure 2A). The mutant
form hMYH R260Q displayed reduced ability to excise adenines
from an A:8oxoG duplex, cleaving only 15% of the substrate as
compared with complete removal by WT hMYH with 18 ng enzyme
(Figure 2A). By increasing the amount of hMYH R260Q up to 240
ng, 40% cleavage of the A:8oxoG duplex was obtained (Figure 2B).
For A:G-containing substrates, R260Q was almost inactive (1%
compared with 36% cleavage by WT hMYH with 18 ng enzyme)
(Figure 2A). Despite its reduced DNA glycosylase activity, EMSAs
revealed that R260Q has retained the ability to bind A:8xoG-
containing duplexes and for the A:G substrate R260Q binds even
stronger than the WT hMYH (Figure 2C). It appears that the hMYH
R260Q substitution results in loss of the ability to discriminate be-
tween A:8oxoG and A:G when binding to DNA. The mutant hMYH
S501F binds the two substrates with similar afﬁnities as the WT
enzyme, whereas no shift was observed with the H434D mutant
neither for A:8oxoG nor for A:G substrates (Figure 2C). With higher
protein concentration, H434D could bind weakly to the A:G sub-
strate but not to A:8oxoG (data not shown). Under conditions for
EMSA, no cleavage of the DNA substrates was observed as assayed
by running a small sample of the reaction mixture on a denaturing/
urea gel (data not shown). In summary, two of the hMYH mutations
identiﬁed (R260Q and H434D) lead to proteins with defect DNA
glycosylase activity.
Analysis of hOGG1
Sequencing of hOGG1 revealed ﬁve novel mutations: one in the con-
trol group (G308E) and four in PSC patients (S31P, V58 synonymous,
G342 synonymous and T398S; Table I). As two of the mutations
found in the PSC group are silent mutations and one is conservative
(T398S), we proceeded with functional studies of the hOGG1 S31P
mutation only (Figure 1B). hOGG1 S31P was expressed in E.coli,
puriﬁed (supplementary Figure 1 is available at Carcinogenesis On-
line) and subjected to 8oxoG DNA glycosylase analysis. hOGG1
S31P showed the same capacity as WT hOGG1 to remove 8oxoG
from an 8oxoG:C DNA duplex (Figure 3A). EMSA reveals that WT
and S31P bind with the same afﬁnity to an 8oxoG:C DNA oligonu-
cleotide (Figure 3B). The alteration S31P does not seem to affect the
activity nor DNA binding capacity of hOGG1.
Analysis of NEIL1
In NEIL1, three novel mutations were found; one in the PSC group
(E181K), one in the PSC-CCA group (H275 synonymous) and one in
the healthy control group (R339W). E181K and the SNP G83D were
subjected for functional studies. Based on a comparison with the
E.coli endonuclease VIIIstructure incomplexwith DNA(34), glycine
83 is found in a loop that forms part of the groove of NEIL1 in which
the DNA is expected to bind, whereas glutamate 181 is a conserved
residue within the helix-2-turn-helix motif that interacts with the
lesion-containing strand (Figure 1C). The NEIL1 E181K protein
was produced in E.coli, but the protein formed inclusion bodies
and we were not able to obtain a pure preparation. NEIL1 G83D
was puriﬁed to apparent homogeneity (supplementary Figure 1 is
available at Carcinogenesis Online), tested for co-purifying contam-
inating activities (supplementary Figure 2 is available at Carcino-
genesis Online) and assayed toward several oxidative DNA lesions
known to be removed by NEIL1. Because NEIL1 has been shown to
Table I. Sequence changes and allele frequencies in four DNA repair genes
a in healthy, PSC and PSC-CCA populations
Gene Reference/variant
allele
Major/minor
allele
Homozygotic or
heterozygotic
SNP/mutation
dbSNP ID Amino acid
change
Amino acid sequence
accession number
Minor allele frequency
Healthy PSC PSC-CCA
hMYH agcc(G/A)tggg G/A Het rs3219484 Val22Met AAC50618 0.21 0.07 0.11
agcc(G/A)tggg —/A Homo rs3219484 Val22Met AAC50618 0 0.03 0
acag(G/C)aggt
b G/C Het — Glu155Gln AAC50618 0.03 0 0
gccc(G/A)gcca G/A Het — Arg260Gln
c AAC50618 0 0.03 0
gaca(G/C)tgcc G/C Het rs3219489 Gln324His AAC50618 0.34 0.41 0.35
gaca(G/C)tgcc —/C Homo rs3219489 Gln324His AAC50618 0.03 0 0.08
ctct(C/G)acat C/G Het — His434Asp
c AAC50618 0 0.03 0
tcct(C/T)tccg C/T Het — Ser501Phe
c AAC50618 0 0.03 0.03
hOGG1 tcgc(T/C)ctga T/C Het — Ser31Pro
c BAA19103.1 0 0.03 0
gtgt(A/T)ctag A/T Het — Val58 BAA19103.1 0 0.03 0
tggg(G/A)acct G/A Het — Gly308Glu BAA19103.1 0.03 0 0
caat(C/G)ccgc C/G Het rs1052133 Ser326Cys BAA19103.1 0.41 0.48 0.30
caat(C/G)ccgc —/G Homo rs1052133 Ser326Cys BAA19103.1 0.10 0.07 0.05
aagg(C/A)cccc C/A Het — Gly342 O15527-4
d 0 0.07 0
atga(C/G)ccag C/G Het — Thr398Ser O15527-4
d 0 0.03 0
NEIL1 tccg(G/A)ctct G/A Het rs5745906 Gly83Asp
c Q96FI4 0 0 0.05
ggca(G/A)agat G/A Het — Glu181Lys
c Q96FI4 0 0.03 0
ggca(T/C)ggcc T/C Het — His275 Q96FI4 0 0 0.03
ccag(C/T)ggcc C/T Het — Arg339Trp Q96FI4 0.03 0 0
NUDT1 ggac(G/A)tgca G/A Het rs4866 Val83Met CAG28583.1 0.03 0.10 0
ccga(C/T)gaca C/T Het rs1799832 Asp119 CAG28583.1 0.45 0.31 0.32
ccga(C/T)gaca —/T Homo rs1799832 Asp119 CAG28583.1 0.07 0 0.03
aNo genetic alterations were identiﬁed in the ﬁfth gene sequenced; NTHL1.
bPart of this sequence is intronic.
cAmino acid changes subjected for functional studies.
dName of an alternative transcript.
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1149process b,d-elimination activity (30,35), its activity assay does not
need NaOH treatment to detect strand breaks as for hMYH and
hOGG1. In contrast to the WT enzyme, NEIL1 G83D showed no
activity on 8oxoG:C duplex DNA and had strongly impaired cleav-
age activity on DHT duplex DNA (Figure 4A). The residual mutant
activity on DHT:A was ,10% of WT activity. WT NEIL1 is shown
previously not to possess 8oxoG (36) or DHT DNA glycosylase
activity on single-stranded DNA (ssDNA; our unpublished observa-
tion). As expected, the G83D mutant protein showed no activity on
ssDNA containing a single 8oxoG or DHT (data not shown). An-
otheroxidativepyrimidinelesion cleaved by NEIL1 is Tg. WT Neil1
has higher activity for Tg in double-stranded DNA than in single
stranded (Figure 4A). The mutant G83D had weak activity for Tg in
double-stranded DNA and almost no cleavage was observed for the
single-stranded Tg substrate. Moreover, removal of formamidopyr-
imidine by G83D NEIL1 was strongly impaired as compared with
the WT enzyme (Figure 4B). These data demonstrate an important
role of Gly83 in substrate recognition.
Next, we tested NEIL1 G83D activity toward other oxidative py-
rimidine lesions such as 5ohC and 5ohU. In contrast to the data above,
NEIL1 G83D cleaved 5ohC:G (Figure 4A) and 5ohU:G (data not
shown) duplex DNA at the same efﬁciency as the WTenzyme (Figure
4A). Also for 5ohC and 5ohU on ssDNA, G83D showed almost the
same cleavage activity as the WT enzyme (Figure 4A). However,
NEIL1 G83D showed signiﬁcantly reduced d-elimination activity
(50%) as compared with the WT enzyme for both single-stranded
substrates. With high concentration of G83D and 5ohC and 5ohU
ssDNA substrates, there appears to be some 5#-phosphtase or ssDNA
nuclease contamination in the reactions. As this is not observedfor the
Tg single-stranded substrate, the possible contaminating activity
might be sequence dependent. To further characterize NEIL1
G83D, EMSAs were performed. The results reveal that G83D binds
to 5ohC:G DNA substrate with slightly reduced afﬁnity as compared
with WT NEIL1 (Figure 4C). In the lane with the highest concentra-
tion of WT NEIL1 (100 ng), there is a 25% reduction in total signal
intensity that might be ascribed to copurifying contaminating 5#-
phosphatase/exonuclease activity.
To further investigate the role of the G83D mutation on the b,d-
reaction, we examined cleavage of a duplex oligonucleotide contain-
ing a single abasic site. Surprisingly, we ﬁnd that the mutant enzyme
incise the abasic site more efﬁciently (two times) than the WT (Figure
4A). However, only 50% of the cleaved abasic site has been fully
processed to the d-elimination end product by NEIL1 G83D, whereas
50% of the cleaved product remains as the b-elimination intermediate.
With WT NEIL1 almost 100% of the cleavage product has been fully
processed to the d-elimination product. It thus appears that the NEIL1
G83D mutation modulates the catalytic capacity of NEIL1 as well as
substrate speciﬁcity.
Intracellular localization studies have revealed that NEIL1 is lo-
cated to the nucleus of human cells with an accumulation in the
Fig. 1. Schematic diagram and 3D structures of hMYH, hOGG1 and NEIL1. (A) Schematic diagram of the hMYH showing functional domains (left) and 3D
structure (right) of MutY from Bacillus stearothermophilus in complex with DNA [Protein Data Bank identiﬁer 1RRQ] (31). The positions of the mutations
studied in this work, R260 and H434 are shown and were identiﬁed by amino acid sequence alignment of hMYH with BsMutY. Serine501 is outside of the ordered
structure. (B) Schematic diagram showing functional domains (left) and 3D structure (right) of hOGG1 in complex with 8oxoG-containing DNA (Protein Data
Bank identiﬁer 1EBM) (32). The location of S31P mutation is shown. (C) Schematic diagram of NEIL1 showing functional domains (left) and 3D structure (right)
(Protein Data Bank identiﬁer 1TDH) (33) with position of G83 and E181 indicated. For hMYH domains interacting with RPA, MSH6, APE1 and PCNA are
indicated. hOGG1 and NEIL1 have a conserved domain (blue) and the NEIL1 C-terminus is necessary for interactions with PCNA, DNA ligase III, DNA
polymerase b and XRCC1. The ﬁgures are not drawn to scale. Fe-S, Iron-sulfur cluster; H2TH, helix-2-turn-helix motif; HhH, helix-hairpin-helix motif; MTS,
mitochondrial targeting signal; NLS, nuclear localization signal; Zn, zinc ﬁnger domain.
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terminus of NEIL1 (Figure 1C) (30). Constructs of NEIL1 G83D and
E181K fused to enhanced green ﬂuorescent protein were generated and
used for transfection of HeLa S3 cells.Fluorescence microscopy showed
that the distribution of the NEIL1 mutants was conﬁned to the nucleus as
seen for WT NEIL1 (Figure 4D). Although we were not able to purify
recombinant NEIL1 E181K expressed in E.coli, the corresponding
fusion protein localized as WT NEI L 1i nH e L ac e l l si n d i c a t i n gt h a t
the mutant is folded and distributed correctly in mammalian cells.
Discussion
PSC is a chronic inﬂammatory disorder of the bile ducts in which the
patients have a high risk for developing CCA. In order to better un-
derstand individual susceptibility to CCA, we evaluated the role of
SNPs and germ line mutations in genes involved in the repair of
oxidative DNA damage. Eighteen genetic variants were identiﬁed,
six were validated SNPs, whereas 12 were new mutations. Three rare
variants identiﬁed in PSC and PSC-CCA patients were found to crit-
ically affect protein function (hMYH R260Q, hMYH H434D and
NEIL1 G83D).
Importantly, there is increasing awareness of the contribution from
rare variants to the genetic susceptibility of complex traits (37). The
detection of such variants is inert to the association study design and
requires resequencing of entire study populations with subsequent
assessment of functional consequences of identiﬁed variants (re-
viewed in ref. 38). Noteworthy, the three variants with severe conse-
quence for the BER pathway were found among patients with PSC
with or without CCA. The lack of overall association between any of
the investigated variants and PSC or CCA susceptibility may clearly
result from lack of statistical power. For instance, it is well established
that the oxidative DNA lesion 8-oxoguanine is mutagenic and that
hOGG1 represents the major 8oxoG removingactivity in human cells.
hOGG1 S326C is the most studied SNP in hOGG1 and is weakly
Fig. 2. Analysis of hMYH variants. (A) Adenine DNA glycosylase activities of hMYH WT, R260Q, H434D and S501F variants were measured by incubating the
respective proteins (18 ng) with a duplex oligodeoxyribonucleotide containing a single A:8oxoG or A:G basepair at 37C for 30 min. Strand cleavage after NaOH
treatment was analyzed by 20% polyacrylamide gel electrophoresis and phosphorimaging (I 5 intact strand and C 5 cleavage product). (B) Different amounts
(0.6–240 ng) of hMYH WT (h), R260Q (:), H434D (X) and S501F ( ) were assayed for A:8oxoG DNA glycosylase activities and percentage strand cleavage
quantiﬁed with ImageQuant. Extract from Escherichia coli cells expressing empty vector and puriﬁed similarly as hMYH was used to measure the background
level (r). (C) DNA binding properties of hMYH WT, R260Q, H434D and S501F (24 ng) to substrates containing A:8oxoG (left panel) or A:G (right panel). After
incubation on ice, DNA–protein complexes (B 5 bound substrate) were separated from free DNA (F) by 10% native polyacrylamide gel electrophoresis. Control
lanes were without addition of protein.
Fig. 3. Analysis of hOGG1 variants. (A) 8oxoG DNA glycosylase activity of
S31P compared with WT hOGG1. A total of 3 and 10 ng enzymes were
incubated with an 8oxoG:C oligonucleotide at 37C for 30 min before
cleavage of the phosphodiester backbone by NaOH. The reaction products
were separated by 20% polyacrylamidegel electrophoresis and visualized by
phosphorimaging. (I 5 intact strand and C 5 cleavage product). (B)D N A
binding properties of hOGG1 WT and S31P. WT and S31P hOGG1 (10, 30
and 100 ng) were incubated with 8oxoG:C DNA on ice and DNA–protein
complexes (B 5 bound substrate) were separated from free DNA (F) by 10%
native polyacrylamide gel electrophoresis. Control lanes were without
addition of protein.
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glycosylase activity (39). Power calculations based on previous stud-
ies of this SNP [odds ratio of GG versus CC genotypes .2.0; (14)]
emphasized limitations of the genetic association study design (0.11
for PSC-CCA versus PSC without CCA, 0.14 for PSC-CCA versus
healthy controls; http://medipe.psu.ac.th/episoft/pssamplesize) to
conclusively clarify whether this mutation may play a role in chol-
angiocarcinogenesis in PSC. Although comparable frequencies of
S326C were observed in all three study populations, the possibility
thus needs to be kept open that weak effects on CCA susceptibility
from this variant may exist.
Two common hMYH mutations associated with colorectal adenoma
polyposis are Y165C and G382D, which account for  73% of all
hMYH mutations reported to date (reviewed in ref. 40). Neither of
these two mutations was found in our study. To date .80 different
hMYH mutations have been described in MutY associated-polyposis
patients (reviewed in ref. 41). Approximately 15% of these mutations
have been subjected to functional studies and several of the mutants
show reduced or no DNA glycosylase activity (41,42). The catalyti-
cally impaired hMYH variant R260Q was found in one patient car-
rying this mutation on one allele. The importance of the mutation for
this patient is uncertain, as hMYH mutations associated with colon
cancer are autosomal recessive. However, R260Q still binds DNA and
may prevent access for WT hMYH to A:8oxoG pairs. The same
mutation was also identiﬁed in a large multisite, population-based
colorectal cancer case–control study (42,43) and was further analyzed
by Ali et al. (42). Similarly as in this work, reduced A:8oxoG activity
was found for R260Q. Our data show that R260Q has normal A:8ox-
oG binding, however, Ali et al. reported that the mutant has reduced
A:8oxoG DNA-binding property. We do not know the reason for the
discrepancy but different assay conditions could contribute. The cat-
alytic impairment of hMYH R260Q was unexpected from a structural
point of view as R260is located on the surface of MutY pointing away
from the active site pocket (Figure 1A). From the structure, this res-
idue is predicted to have no role in catalysis or in DNA binding as the
distance from R260 to the adenine-binding pocket is .16 A ˚. Future
screening for hMYH associated mutations in cancer should also in-
clude R260Q.
The C-terminal domain of MutYis required for 8oxoG recognition
and deletion of this domain results in a protein with reduced binding
afﬁnity and DNA glycosylase activity for A:8oxoG but not for A:G
(44,45). The H434 residue is a conserved residue within the C-
terminal domain and is part of a loop that intercalates the DNA and
makes contacts with the sugar-phosphate backbone 5# to the oxidized
guanine. The presence of aspartate in this position will result in a
negative charge and repulsion of the DNA, as demonstrated by the
lack of shift in the EMSAs for hMYH H434D. Interestingly, the
H434D mutant has the same DNA glycosylase activity for A:8oxoG
as WT hMYH; however, the ability to excise adenine from A:G mis-
pairs is signiﬁcantly reduced, supporting a previous observation
that the C-terminal domain is not only involved in 8oxoG recognition
but also affects binding and catalytic activities toward A:G mis-
matches (46).
The NEIL1 G83D mutant has been shown previously to lack DNA
glycosylase activity toward Tg and faPy lesion but has b-elimination
activity on AP DNA (47). Presumably, the gain of the acidic aspartate
alters the surface of the active site of NEIL1 that is dominated by
basic amino acid side chains in the WT enzyme. Here, we show that
the DNA glycosylase activity for G83D is lost only for 8oxoG, DHT
and Tg, substrates that all need to be in a context of double-stranded
DNA for NEIL1 to cleave. For lesions known to be substrates for
NEIL1 also when present in ssDNA (5ohC, 5ohU), G83D is as active
as WT NEIL1. In addition to compromised DNA glycosylase activity
for G83D for some substrates, the d-elimination reaction is also af-
fected. After incubation with G83D, about half of the substrate was
cleaved by b,d-elimination and the other half by b-elimination only.
Fig. 4. Analysis of NEIL1 variants. (A) DNA glycosylase activity of G83D compared with WT NEIL1. Enzymes (2, 5, 10 and 20 ng) were incubated with
different oligonucleotide substrates as indicated at 37C for 30 min. The reaction products were separated by 20% polyacrylamide gel electrophoresis and
visualized by phosphorimaging. (I 5 intact strand, C 5 cleavage product, b 5 b elimination, d 5 d elimination cleavage, ss 5 single strand). (B) FaPy DNA
glycosylase activity of NEIL1 WT (r) and G83D (n). Enzymes (3, 10, 30 and 100 ng) were assayed for removal offaPy from [3H]-methyl-faPy-poly(dG dC). (C)
DNA binding properties of NEIL1 WT and G83D. NEIL1 WT and G83D (20, 50 and 100 ng) were incubated with 5ohC:G DNA on ice and DNA–protein
complexes (B 5 bound substrate) were separated from free DNA (F) by 10% native polyacrylamide gel electrophoresis. Control lanes were without addition of
protein. (D) Nuclear localization of NEIL1 G83D and E181K. Asynchronous growing HeLa S3 cells were transiently transfected with constructs expressing
NEIL1-EGFP, NEIL1G83D-EGFP or NEIL1E181K-EGFP. Cells were imaged directly by ﬂuorescence microscopy for EGFP detection. DNA was stained with
Hoechst 33342.
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and for the AP DNA. It thus appears that introduction of an aspartic
residue at this position directly or indirectly affects residues involved
in d-elimination. Roy et al. (47) reported that G83D yielded primarily
b-elimination only. Wedonotknowthereasonforthisdiscrepancybut
might be due to different assay conditions, variation during expression
and puriﬁcation or the sequence context of the DNA substrate.
Residue G83 is part of a loop connecting b-strands 4 and 5, which
in the E.coli EndoVIII structure includes the essential DNA-interca-
lating residue Leu70 (corresponding to Met81 in NEIL1). Modeling
of aspartate in position 83 of NEIL1 suggests that this mutation alter
the conformation of this loop, as the negatively charged aspartate side
chain is pointing into a hydrophobic pocket in NEIL1. Signiﬁcant
rearrangement of this loop is expected in order to remove unfavorable
steric and electrostatic conﬂicts following a mutation of Gly83 into
Asp. Interestingly, according to our model, this loop is close to the
non-lesion-containing strand, supporting the observed effect on
double-stranded substrates only.
TheNEIL1G83DSNPwasfoundintwoPSCpatientswithCCAand
both were heterozygotic for this polymorphism. As the other allele is
healthy, the cells are probably to function with approximately half the
level of normal NEIL1 activity. In tissue with severe oxidative stress,
such as the bile ducts of PSC patients, a reduction in the DNA repair
functions could lead to high levels of oxidative DNA damage and con-
sequently, an increase in the incidence of gene mutations might be the
result. Further, defect in one allele could be fatal if the other allele
acquires mutations during initial stages of carcinogenesis. It has been
estimated that a 20–35% reduction in repair capacity of cells is associ-
ated with a 4- to 6-fold higher risk of developing cancer (48).
An expression study has shown previously that the NEIL1 messen-
ger RNA level was reduced in about half of primary gastric cancer
specimens examined indicating a role of NEIL1 in preventing cancer
development (12). Variations in expression levels of NEIL1 and also
of the other DNA repair genes analyzed may also be of signiﬁcance
for CCA in PSC patient. However, the inﬁltrating nature of CCA
tumors makes it difﬁcult to obtain pure tumor material and such
a study awaits further work.
In conclusion, by sequencing a panel of genes encoding proteins of
the BER pathway in patients with PSC, PSC and CCA and healthy
controls, we detected nine novel non-synonymous mutations in
hMYH, hOGG1 and NEIL1. Although no statistical signiﬁcant differ-
ences in allele frequencies between any of the investigated groups
were found, severe impairment of protein function was evident in
extensive functional analysis of three mutations found in patients with
PSC and PSC with CCA. In statistical terms, a causal relationship
between either of these mutations and carcinogenesis and PSC is
difﬁcult to conclude. Nevertheless, our present ﬁndings add to in-
creasing knowledge of the importance of rare, coding variants in
complex diseases (37,49) and hint to the usefulness of massive se-
quencing in the search for genetic variants that inﬂuence the individ-
ual susceptibility to cancer development.
Supplementary material
Supplementary Tables 1 and 2 and Figures 1 and 2 can be found at
http://carcin.oxfordjournals.org/
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